MAP2K7 and colorectal carcinoma: Currently, several pilot trials and clinical studies aim at simultaneously inhibiting EGFR and BRAF or MEK for treatment of BRAF-mutant (or KRAS-mutant) CRC patients, in order to block both, the oncogenic RAF-MEK-ERK signal, as well as the feedback loop via EGFR family members (Fig. 3, Table 1).